Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) plus androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis): Post hoc analysis of the phase 3 ARCHES trial.

被引：3

作者：

Armstrong, Andrew J.

Iguchi, Taro

Azad, Arun

Szmulewitz, Russell Zelig

Holzbeierlein, Jeffrey

Villers, Arnauld

Alcaraz, Antonio

Alexeev, Boris

Shore, Neal D.

Gomez-Veiga, Francisco

Rosbrook, Brad

Zohren, Fabian

Yamada, Shunsuke

Haas, Gabriel P.

Stenzl, Arnulf

机构：

[1] Duke Canc Inst, Ctr Prostate & Urol Canc, Durham, NC USA

[2] Kanazawa Med Univ, Dept Urol, Kanazawa, Ishikawa, Japan

[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[4] Univ Chicago, Chicago, IL 60637 USA

[5] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[6] Lille Univ, Univ Hosp Ctr, Dept Urol, Lille, France

[7] Hosp Clin Barcelona, Dept Urol, Barcelona, Spain

[8] Hertzen Moscow Canc Res Inst, Dept Oncol, Moscow, Russia

[9] Carolina Urol Res Ctr, Myrtle Beach, SC USA

[10] Hosp Univ Salamanca, GITUR IBSAL, Salamanca, Spain

[11] Pfizer Inc, New York, NY USA

[12] Astellas Pharma Inc, Data Sci, Northbrook, IL USA

[13] Astellas Pharma Inc, Dept Oncol, Northbrook, IL USA

[14] Eberhard Karls Univ Tubingen, Univ Hosp, Tubingen, Germany

来源：

关键词：

D O I：

10.1200/JCO.2022.40.6_suppl.115

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

115

引用

页数：4